CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00132028
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:41.797210+00:00
Published At: 2012-09-19T00:00:00+00:00
Record Updated At: 2014-05-23
Results Posted At: 2012-09-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Adult Favorable Prognosis Hodgkin Lymphoma", "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Adult Unfavorable Prognosis Hodgkin Lymphoma", "Recurrent Adult Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2014-05-23"
protocolSection.identificationModule.nctId: "NCT00132028"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin\u0027s Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2012-09-19"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.